Free Newsletter
P&G's drugs could go on the block
Free newsletter via e-mail
Tools
Procter & Gamble is cutting research and development of its pharmaceutical products and could sell some or all of its pharma brands, including the widely used osteoporosis med Actonel. Report
More stories about Procter & Gamble
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: